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Summary  Idiopathic  recurrent  pericarditis  (IRP)  impairs  quality  of  life.  Although  its  precise
etiology is  not  certain,  it  is  believed  to  be  immunologically  mediated.  Its  optimal  treatments  are
unknown. Initial  therapy  is  with  non-steroidal  anti-inﬂammatory  drugs  and  colchicine.  Steroids,
which are  often  used,  however  may  promote  recurrences.  European  guidelines  advocate  aza-
thioprine or  cyclophosphamide  in  refractory  cases  despite  limited  evidence.  We  report  two
adults with  IRP  successfully  treated  with  the  interleukin-1  antagonist,  anakinra.  We  combine
this experience  with  the  ﬁrst  systematic  literature  review  of  immunosuppression  in  IRP.  A  total
of 8  papers  were  included  in  the  review,  which  alongside  our  patients  described  18  cases.  The
best treatments  comprised  anakinra  and  intravenous  immunoglobulin,  with  respective  remis-
sion rates  of  100%  and  67%.  Cyclophosphamide  and  azathioprine  were  less  efﬁcacious.  The
unprovoked  inﬂammatory  episodes  in  our  patients  alongside  their  prompt  response  to  anakinra
indicate that  in  some  instances  IRP  may  represent  an  autoinﬂammatory  condition.  We  suggest
that in  IRP  refractory  to  initial  treatment,  anakinra  should  be  considered  as  a  potential  therapy.
Clinical trials  are  required  to  conﬁrm  its  beneﬁts  in  IRP.
 Car© 2011  Japanese  College  of∗ Corresponding author at: Department of Rheumatology, Guy’s
Hospital, Great Maze Pond, London SE1 9RT, UK.
Tel.: +44 20 7188 5900; fax: +44 20 7407 7532.
E-mail address: ian.c.scott@btinternet.com (I.C. Scott).
I
I
a
I
o
t
1878-5409/$ — see front matter © 2011 Japanese College of Cardiology. 
doi:10.1016/j.jccase.2011.07.003diology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
ntroduction
diopathic  recurrent  pericarditis  (IRP)  complicates  30%  of
cute  pericarditis  cases.  Although  rarely  life-threatening,
RP  is  painful  and  signiﬁcantly  impairs  quality  of  life.  Its  eti-
logy  is  uncertain;  it  may  follow  an  initial  viral  infection  that
riggers  further  immunologically  mediated  episodes.
Published by Elsevier Ltd. All rights reserved.
e I.C.  Scott  et  al.
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Figure  1  Clinical  course  and  treatment  responses  of  two
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Initial  treatment  involves  non-steroidal  anti-
nﬂammatory  drugs  (NSAIDs)  and  colchicine.  Corticosteroids
re  effective  in  the  short-term,  however  as  they  may
ncrease  the  risk  of  recurrence  other  immunosuppressants
re  often  required.  Current  European  guidelines  advocate
zathioprine  or  cyclophosphamide  as  ﬁrst-line  agents
espite  limited  supporting  evidence.  More  recently  the
nterleukin-1  (IL-1)  receptor  antagonist,  anakinra  has  been
uccessfully  used  in  3  children  with  IRP,  suggesting  this
ytokine  has  a  key  pathogenic  role  [1].
We  provide  further  evidence  for  the  efﬁcacy  of  anakinra
n  IRP  by  reporting  its  use  in  two  adult  patients.  Given  the
ncertainty  regarding  the  optimal  treatment  of  this  condi-
ion,  we  combined  our  experience  with  the  ﬁrst  systematic
iterature  review  of  immunosuppression  in  IRP.
ase report 1
 33-year-old  female  presented  in  2007  with  2  weeks  of  peri-
arditic  pain.  She  reported  several  previous  milder  episodes.
er  C-reactive  protein  (CRP)  was  raised  at  221  mg/l.
mmunological  tests  (antinuclear  antibodies,  antineutrophil
ytoplasmic  antibodies,  dsDNA,  rheumatoid  factor,  lupus
nticoagulant,  antiphospholipid  antibodies)  and  infection
creens  (blood  cultures  and  serology  for  mycoplasma,
egionella,  cytomegalovirus,  hepatitis,  and  human  immun-
deﬁciency  virus)  were  negative.  She  had  neither  recurrent
evers  nor  features  of  a  rheumatic  disease  and  genetic
equencing  of  MEFV  and  TNFRSF1A  —  responsible  for  famil-
al  Mediterranean  fever  (FMF)  and  tumor  necrosis  factor
TNF)  receptor  associated  periodic  syndrome,  respectively
 were  normal.  Prednisolone  was  initiated  with  a  prompt
linical  response;  her  CRP  fell  to  83  mg/l  within  36  h.
wo  weeks  later  she  was  asymptomatic.  On  discontinuing
teroids  she  immediately  relapsed  (CRP  358  mg/l);  steroids
ere  restarted.  Despite  the  addition  of  regular  colchicine
nd  methotrexate,  her  pericarditis  relapsed  on  three  further
ccasions  over  3  months.
Treatment  with  anakinra  was  commenced  in  2008
nabling  prednisolone  and  methotrexate  withdrawal  with-
ut  disease  recurrence.  In  2009  she  was  completely  well  on
nakinra  and  colchicine.  A  trial  of  anakinra  withdrawal  was
ollowed  within  one  week  by  ﬂorid  pericarditis  that  promptly
esolved  after  restarting  anakinra.  Eighteen  months  later
he  remains  in  remission  on  anakinra  and  colchicine.
ase report 2
 28-year-old  male  presented  in  August  2000  with  acute  peri-
arditis.  Over  the  following  4  years  he  had  numerous  further
ttacks  characterized  by  typical  pain,  pericardial  effusions
nd  a  marked  acute  phase  response,  which  responded  lit-
le  to  NSAIDs.  His  autoimmune  serology  and  MEFV  genotype
ere  normal.  A  diagnosis  of  IRP  was  made  and  colchicine  ini-
iated,  with  minimal  beneﬁt.  In  December  2004  he  became
cutely  unwell  with  severe  pericarditic  pain,  arthralgia,
nemia,  and  thrombocytopenia  that  responded  to  pred-
isolone.  Etanercept  was  introduced  with  the  hope  it  might
acilitate  prednisolone  tapering,  but  this  prompted  further
RP  ﬂares.  In  February  2005,  etanercept  was  replaced  by
T
I
matients  with  idiopathic  recurrent  pericarditis  (IRP).  (a)  Case
 and  (b)  Case  2.
nakinra  with  dramatic  efﬁcacy.  Steroids  were  completely
ithdrawn  and  he  has  had  no  further  ﬂares.
The  clinical  courses  of  our  two  patients  alongside  their
reatment  responses  are  outlined  in  Fig.  1.
iterature review
e  searched  Pubmed,  EMBASE,  and  MEDLINE  up  to  Octo-
er  2010  using  the  following  search  terms:  recurrent  or
hronic  idiopathic  or  relapsing  and  pericarditis  and  immuno-
uppression  or  IL-1  or  interleukin-1  or  anakinra  or  anti-TNF
r  biologic  or  cyclosporin  or  methotrexate  or  azathioprine  or
yclophosphamide  or  mycophenolate.  We  excluded  papers
ot  in  English  or  dealing  with  alternative  diagnoses.
We  identiﬁed  96  citations  and  fully  reviewed  20  reports;
2  were  excluded  (8  were  duplicate  publications,  4  dealt
ith  alternative  diagnoses).  Finally,  8  were  included  (see
able  1  [1—8]), comprising  3  case  reports  and  5  case  series.
Along  with  our  patients  there  were  18  reported  cases  of
RP  treated  with  immunosuppression.  These  comprised  10
ales  and  8  females  (mean  age  25  years;  mean  follow-up  39
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Table  1  Immunosuppressants  used  in  idiopathic  recurrent  pericarditis.
Study Year Cases Age  (years) Sex Follow-up  (months) Immunosuppression Outcome
Bird  and  Mustchin  [2] 1987 1 32 M 60 Azathioprine Remission
Marcolongo  et  al.  [3] 1995 2 56 F 21 Azathioprine Remission
19 M 7 Azathioprine Remission
Lessio  et  al.  [4] 1999 1 44 M 24 Cyclosporin Remission
Tona  et  al.  [5] 2003 2 30 M 42 a.  Azathioprine/Cyclosporin a.  No  response
b. Cyclophosphamide b.  Improved
c. IVIG c.  Remission
19 F 32 a. Cyclophosphamide/Cyclosporin/MTX a.  No  response
b. IVIG b.  Remission
Peterlana et  al.  [6] 2005 4 29 M 32  IVIG  Remission
28 M — IVIG Remission
21 M  —  IVIG  Improved
11 M  —  a.  MTX/Cyclosporin/Azathioprine  a.  No  response
b. IVIG  b.  Improved
Imazio et  al.  [7]  2007  1  45  F  63  a.  Azathioprine  a.  Improved
b. MTX/Cyclosporin  b.  Improveda
Dalla  Pozza  et  al.  [8] 2007 2 12 F 12 Azathioprine/MTX Improved
7 F 68 Azathioprine/MTX/Anti-TNF No  response
Picco et  al.  [1] 2009 3 14 F 15 Anakinra Remissionb
12 M 9 Anakinra Remissionb
13 F 44 a.  MTX a.  No  response
b. Anakinra b.  Remissionb
a Patient died.
b All 3 cases relapsed on stopping anakinra with remission on restarting. IVIG, intravenous immunoglobulin; Anti-TNF, anti-tumor necrosis factor; MTX, methotrexate.
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Figure  2  Outcome  of  immunosuppression  in  idiopathic  recur-
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Rent pericarditis.  TNF,  tumor  necrosis  factor;  IVIG,  intravenous
mmunoglobulin.
onths).  Nine  patients  received  more  than  one  immunosup-
ressant  given  sequentially.
Thirteen  patients  achieved  remission,  4  improved  and  1
howed  no  response.  Their  treatments  and  outcomes  are
hown  in  Table  1  and  Fig.  2.  The  treatments  and  their
emission  rates  comprised  azathioprine  (8  cases,  38%  remis-
ion),  methotrexate  (7  cases,  no  remission),  intravenous
mmunoglobulin  (IVIG)  (6  cases,  67%  remission),  cyclosporin
5  cases,  20%  remission),  anakinra  (5  cases,  100%  remission),
yclophosphamide  (2  cases,  no  remission),  and  anti-TNF  (2
ases,  no  remission).  Methotrexate  was  least  efﬁcacious;
1%  of  patients  did  not  improve.
iscussion
RP  is  a  debilitating  condition  with  a  predilection  for  younger
atients.  Several  immunosuppressants  have  been  used  with
ariable  success.  Although  current  European  guidelines  rec-
mmend  azathioprine  and  cyclophosphamide  as  ﬁrst-line
herapies,  published  data  identiﬁed  from  our  review  sug-
est  these  agents  have  limited  efﬁcacy  (remission  rates  of
8%  and  0%,  respectively).  IVIG  and  anakinra  were  most
fﬁcacious  with  high  remission  rates  of  67%  and  100%,
espectively.  We  suggest  that  current  guidance  requires
eappraisal.
The  etiology  of  IRP  remains  unknown.  It  is  probably  a
eterogeneous  condition  arising  from  several  distinct  patho-
ogical  mechanisms.  There  is  evidence  for  an  auto-immune
rocess  involving  the  adaptive  immune  system,  with  Imazio
t  al.  ﬁnding  anti-nuclear  antibodies  in  43%  of  145  cases  of
ecurrent  pericarditis  [9].  Our  review  supports  an  autoim-
une  process  with  multiple  immune  modulating  treatments
educing  recurrences.  The  excellent  response  to  anakinra
owever  suggests  that  at  least  some  cases  may  be  autoin-
ammatory  in  nature.
Autoinﬂammatory  syndromes  are  a  heterogeneous  group
f  disorders  that  are  characterized  by  episodes  of  apparently
nprovoked  inﬂammation  due  to  activation  of  the  innate
mmune  system.  Because  the  adaptive  immune  system  is  not
nvolved  patients  do  not  exhibit  auto-antibodies.  The  under-
ying  defect  in  these  disorders  appears  to  be  aberrancies
n  pathways  that  regulate  the  inﬂammasome.  The  inﬂam-I.C.  Scott  et  al.
asome  is  an  intracellular  complex,  which  on  detection  of
oreign  pathogens  by  pathogen-recognition  receptors  results
n  an  immune  response  via  activation  of  the  proinﬂammatory
ytokine,  IL-1. It  is  regulated  by  several  different  proteins,
xamples  of  which  include  pyrin  (the  variant  protein  in  FMF)
nd  cryopyrin  (the  variant  protein  in  cryopyrin-associated
eriodic  syndromes).  The  importance  of  IL-1 production  in
hese  diseases  explains  their  response  to  IL-receptor  block-
de  with  anakinra.  The  unprovoked  inﬂammatory  episodes  in
ur  two  patients,  the  absence  of  auto-antibodies,  and  their
ramatic  response  to  anakinra  supports  the  view  of  Picco
t  al.  that  at  least  a  subset  of  patients  with  IRP  have  an
utoinﬂammatory  disease  [1]  and  suggests  such  cases  result
rom  deﬁcient  inﬂammasome  regulation.  Further  support  for
his  concept  comes  from  the  report  of  anakinra  responsive
ericarditis  in  a  patient  with  a  variant  of  cryopyrin  associ-
ted  periodic  syndrome  [10].
Our  review  has  several  limitations.  All  publications  are
ase  reports  or  series,  with  no  clinical  trials  available.
here  is  clinical  heterogeneity  between  patients,  varying
ith  regards  to  age,  disease  duration,  and  previous  treat-
ents.  Finally  the  follow-up  period  is  short  with  long-term
utcomes  unknown.
In  conclusion  our  ﬁndings  support  a role  for  anakinra  in
RP  resistant  to  initial  treatment  with  NSAIDs  and  colchicine.
nakinra  provided  the  best  chance  of  remission  in  published
ases  and  should  be  considered  as  a  potential  treatment  in
efractory  IRP.  Its  beneﬁts  however  require  formal  assess-
ents  in  clinical  trials  of  IRP  patients.
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